As Nlrp3 inflammasome activation through both canonical and non-canonical pathways has been shown to play an important role in the pathology of AD, the Nlrp3 inflammasome has emerged as a possible target for future pharmacological therapies (67, 70, 71). Here, NLRP3 is linked to Alzheimer disease.